Literature DB >> 28812915

Kardiovize Brno 2030, a prospective cardiovascular health study in Central Europe: Methods, baseline findings and future directions.

Narine K Movsisyan1, Manlio Vinciguerra1, Francisco Lopez-Jimenez2, Šárka Kunzová1,3, Martin Homolka1, Jana Jaresova1, Renata Cífková1,4, Ondřej Sochor1,2.   

Abstract

Background Atherosclerotic cardiovascular disease is highly prevalent in Eastern and Central Europe, where the incidence is the highest in the world. The Kardiovize Brno 2030 study was designed as a prospective cohort study to investigate the complex relationships of cardiovascular disease and outcomes with a range of biological, psychosocial, environmental, behavioral, and economic factors in an urban population of the Czech Republic. Methods We randomly selected a 1% sample of the city of Brno residents aged 25-64 years stratified by sex and age. The study assessed traditional and novel cardiovascular disease risk factors, including sociodemographic and smoking status, physical activity, diet, depression, stress, body fat, cardio-ankle vascular index, and intima media thickness, complemented by blood tests; biological samples were stored for future analyses. Results The study enrolled 2160 participants (54.8% women), with a mean age of 47 ± 11.3 years. They were mostly full-time employed (75.6%) and married (62.1%). Hyperlipidemia was highly prevalent (70.7% in men, and 67.1% in women, NS). Hypertension and diabetes mellitus were more prevalent in men than in women (54.3% vs. 38.7% and 7.1% vs. 3.5%, respectively, P < 0.001 for both). A total of 25.3% of men and 21.9% of women smoked, whereas 20.0% and 43.0% of men and 18.1% and 26.6% of women were obese and overweight, respectively. Conclusions Cardiovascular risk factors are highly prevalent in the city of Brno, an urban population from Central Europe. The Kardiovize Brno 2030 study will provide unique multidimensional and longitudinal cardiovascular health data from a region where epidemiological studies are scarce.

Entities:  

Keywords:  Central and Eastern Europe; Prospective cohort study; cardiovascular risk factors; urban population

Mesh:

Year:  2017        PMID: 28812915     DOI: 10.1177/2047487317726623

Source DB:  PubMed          Journal:  Eur J Prev Cardiol        ISSN: 2047-4873            Impact factor:   7.804


  18 in total

Review 1.  Cardiovascular Risk Awareness in the Czech Republic: Can We Implement Effective Measures?

Authors:  Jose Hernandez
Journal:  Curr Atheroscler Rep       Date:  2019-11-09       Impact factor: 5.113

2.  Differences between Slovak and Dutch patients scheduled for coronary artery bypass graft surgery regarding clinical and psychosocial predictors of physical and mental health-related quality of life.

Authors:  Noha El-Baz; Daniela Ondusova; Martin Studencan; Jaroslav Rosenberger; Sijmen A Reijneveld; Jitse P van Dijk; Berrie Middel
Journal:  Eur J Cardiovasc Nurs       Date:  2017-12-12       Impact factor: 3.908

3.  Associations between high triglycerides and arterial stiffness in a population-based sample: Kardiovize Brno 2030 study.

Authors:  Iuliia Pavlovska; Sarka Kunzova; Juraj Jakubik; Jana Hruskova; Maria Skladana; Irma Magaly Rivas-Serna; Jose R Medina-Inojosa; Francisco Lopez-Jimenez; Robert Vysoky; Yonas E Geda; Gorazd B Stokin; Juan P González-Rivas
Journal:  Lipids Health Dis       Date:  2020-07-15       Impact factor: 3.876

4.  Sleep Duration and Excessive Daytime Sleepiness Are Associated with Obesity Independent of Diet and Physical Activity.

Authors:  Andrea Maugeri; Jose R Medina-Inojosa; Sarka Kunzova; Antonella Agodi; Martina Barchitta; Ondrej Sochor; Francisco Lopez-Jimenez; Yonas E Geda; Manlio Vinciguerra
Journal:  Nutrients       Date:  2018-09-03       Impact factor: 5.717

5.  Dog Ownership and Cardiovascular Health: Results From the Kardiovize 2030 Project.

Authors:  Andrea Maugeri; Jose R Medina-Inojosa; Sarka Kunzova; Martina Barchitta; Antonella Agodi; Manlio Vinciguerra; Francisco Lopez-Jimenez
Journal:  Mayo Clin Proc Innov Qual Outcomes       Date:  2019-08-23

Review 6.  Dysglycemia and Abnormal Adiposity Drivers of Cardiometabolic-Based Chronic Disease in the Czech Population: Biological, Behavioral, and Cultural/Social Determinants of Health.

Authors:  Iuliia Pavlovska; Anna Polcrova; Jeffrey I Mechanick; Jan Brož; Maria M Infante-Garcia; Ramfis Nieto-Martínez; Geraldo A Maranhao Neto; Sarka Kunzova; Maria Skladana; Jan S Novotny; Hynek Pikhart; Jana Urbanová; Gorazd B Stokin; Jose R Medina-Inojosa; Robert Vysoky; Juan P González-Rivas
Journal:  Nutrients       Date:  2021-07-08       Impact factor: 6.706

7.  Association of Cardiovascular Health with Epicardial Adipose Tissue and Intima Media Thickness: The Kardiovize Study.

Authors:  Jana Hruskova; Andrea Maugeri; Helena Podroužková; Tatiana Štípalová; Juraj Jakubík; Martina Barchitta; Jose R Medina-Inojosa; Martin Homolka; Antonella Agodi; Sarka Kunzova; Ondrej Sochor; Francisco Lopez-Jimenez; Manlio Vinciguerra
Journal:  J Clin Med       Date:  2018-05-13       Impact factor: 4.241

8.  Association of Dietary Patterns with Metabolic Syndrome: Results from the Kardiovize Brno 2030 Study.

Authors:  Antonella Agodi; Andrea Maugeri; Sarka Kunzova; Ondrej Sochor; Hana Bauerova; Nikola Kiacova; Martina Barchitta; Manlio Vinciguerra
Journal:  Nutrients       Date:  2018-07-13       Impact factor: 5.717

9.  Circulating histone signature of human lean metabolic-associated fatty liver disease (MAFLD).

Authors:  Diana Buzova; Andrea Maugeri; Antonio Liguori; Cecilia Napodano; Oriana Lo Re; Jude Oben; Anna Alisi; Antonio Gasbarrini; Antonio Grieco; Jan Cerveny; Luca Miele; Manlio Vinciguerra
Journal:  Clin Epigenetics       Date:  2020-08-20       Impact factor: 6.551

10.  Translation and validation of the cardiac rehabilitation barriers scale in the Czech Republic (CRBS-CZE): Protocol to determine the key barriers in East-Central Europe.

Authors:  Petr Winnige; Ladislav Batalik; Katerina Filakova; Jakub Hnatiak; Filip Dosbaba; Sherry L Grace
Journal:  Medicine (Baltimore)       Date:  2020-03       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.